Bax mutations and resistance to apoptosis have been described in stomach, pancreas, endometrium, hemopoietic malignancies, and a subset of colon and lung cancers [71,72] indicating that inactivating Bax mutations may play an important role in tumor progression in these cancers. Here, BAX is linked to lung carcinoma.